Literature DB >> 7251903

Adriamycin cardiotoxicity: report of an unusual case with features resembling endomyocardial fibrosis.

W Fitter, D J deSa, K R Pai.   

Abstract

We report on a case of adriamycin cardiotoxicity occurring in a five-year-old boy treated for rhabdomyosarcoma. In addition to the usual features of myofibrillary degeneration associated with adriamycin, extreme endocardial fibrosis and mural thrombosis affecting the apical segments of both ventricles but particularly the left ventricle was seen at necropsy. The changes resembled classical endomyocardial fibrosis.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7251903      PMCID： PMC493621          DOI： 10.1136/jcp.34.6.602

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN： 0021-9746            Impact factor:   3.411


  10 in total

1.  The pathology of endomyocardial fibrosis in Uganda.

Authors:  J N DAVIES; J D BALL
Journal:  Br Heart J       Date:  1955-07

2.  A clinicopathologic analysis of adriamycin cardiotoxicity.

Authors:  E A Lefrak; J Pitha; S Rosenheim; J A Gottlieb
Journal:  Cancer       Date:  1973-08       Impact factor: 6.860

3.  Therapeutic effect and toxicity of adriamycin in patients with neoplastic disease.

Authors:  J J Wang; E Cortes; L F Sinks; J F Holland
Journal:  Cancer       Date:  1971-10       Impact factor: 6.860

Review 4.  Endomyocardial fibrosis in Uganda (Davies' disease). II. An epidemiologic, clinical, and pathologic study.

Authors:  D H Connor; K Somers; M S Hutt; W C Manion; P G D'Arbela
Journal:  Am Heart J       Date:  1968-01       Impact factor: 4.749

5.  Adriamycin-induced myocardial lesions. Report of a workshop.

Authors: 
Journal:  Am J Surg Pathol       Date:  1977-03       Impact factor: 6.394

Review 6.  Endomyocardial fibrosis in Uganda (Davies' disease). 1. An epidemiologic, clinical, and pathologic study.

Authors:  D H Connor; K Somers; M S Hutt; W C Manion; P G D'Arbela
Journal:  Am Heart J       Date:  1967-11       Impact factor: 4.749

7.  Clinical trials with adriamycin.

Authors:  E Middleman; J Luce; E Frei
Journal:  Cancer       Date:  1971-10       Impact factor: 6.860

8.  Phase I and preliminary phase II evaluation of adriamycin (NSC 123127).

Authors:  G Bonadonna; S Monfardini; M De Lena; F Fossati-Bellani; G Beretta
Journal:  Cancer Res       Date:  1970-10       Impact factor: 12.701

9.  Cardiotoxicity of adriamycin and related anthracyclines.

Authors:  L Lenaz; J A Page
Journal:  Cancer Treat Rev       Date:  1976-09       Impact factor: 12.111

10.  Endomyocardial fibrosis associated with daunorubicin therapy.

Authors:  R G Wilcox; P D James; P J Toghill
Journal:  Br Heart J       Date:  1976-08
  10 in total
  1 in total

Review 1.  Novel Therapeutics for Anthracycline Induced Cardiotoxicity.

Authors:  Jacqueline T Vuong; Ashley F Stein-Merlob; Richard K Cheng; Eric H Yang
Journal:  Front Cardiovasc Med       Date:  2022-04-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.